"Bayer shares soar 11% after key U.S. legal win against Roundup cancer claims," 16 August 2024

Bayer shares jumped in morning trade as the German life sciences company said it scored a legal victory in its suit over claims that exposure to its popular Roundup weed killer led to cancer...

The company... announced that the 3rd U.S. Circuit Court of Appeals in Philadelphia found in its favor against plaintiff David Schaffner’s claim alleging that Monsanto... violated state law by failing to add a cancer warning to the Roundup label.

Schaffner was diagnosed with non-Hodgkin’s lymphoma... partly citing a loss of consortium, which refers to the impact of his illness on their relationship...

Bayer has been mired in legal conflict over Roundup, with Reuters estimating that 165,000 charges were brought against the product in the U.S., of which roughly 54,000 reportedly remain as of August, following a $10.9 billion settlement in 2020.

...Bayer noted that the Philadelphia ruling conflicts with decisions made by other federal appeal courts and called upon the U.S. Supreme Court to preside.

“This decision on federal preemption, a cross-cutting issue in this litigation, creates a circuit split among the federal appellate courts and necessitates a review by the U.S. Supreme Court to settle this important issue of law,” Bayer said, adding it is “considering the impact of this ruling on other pending litigation and looks forward to presenting its arguments, as fully embraced by the Third Circuit, to the U.S. Supreme Court.”